Abstract
MicroRNAs (miRNAs) are a class of small (18~25 nucleotides long) non-coding RNAs that regulate gene expression on the post-transcriptional level. During the last decade, the field of miRNA research has been exponentially expanding, revealing the widespread role of these molecules in numerous biological processes. Aberrant miRNA expression has been documented in multiple haematologic malignancies, including B cell lymphomas. There is compelling evidence that miRNAs can function as oncogenes or tumor suppressor genes in lymphoid malignancies. In this review, we recapitulate the current knowledge of miRNA expression in B cell malignancies and discuss the accumulating evidence for a major role of miRNA deregulation in the development of B cell-derived lymphoid tumors.
Keywords: B cells, Hodgkin lymphoma, leukemia, lymphoma, MicroRNA.
Current Molecular Medicine
Title:Role of MicroRNAs in B Cell Leukemias and Lymphomas
Volume: 14 Issue: 5
Author(s): A. Schmidt and R. Kuppers
Affiliation:
Keywords: B cells, Hodgkin lymphoma, leukemia, lymphoma, MicroRNA.
Abstract: MicroRNAs (miRNAs) are a class of small (18~25 nucleotides long) non-coding RNAs that regulate gene expression on the post-transcriptional level. During the last decade, the field of miRNA research has been exponentially expanding, revealing the widespread role of these molecules in numerous biological processes. Aberrant miRNA expression has been documented in multiple haematologic malignancies, including B cell lymphomas. There is compelling evidence that miRNAs can function as oncogenes or tumor suppressor genes in lymphoid malignancies. In this review, we recapitulate the current knowledge of miRNA expression in B cell malignancies and discuss the accumulating evidence for a major role of miRNA deregulation in the development of B cell-derived lymphoid tumors.
Export Options
About this article
Cite this article as:
Schmidt A. and Kuppers R., Role of MicroRNAs in B Cell Leukemias and Lymphomas, Current Molecular Medicine 2014; 14 (5) . https://dx.doi.org/10.2174/1566524014666140603095414
DOI https://dx.doi.org/10.2174/1566524014666140603095414 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Repressing the Activity of Protein Kinase CK2 Releases Mitochondria-Mediated Apoptosis in Cancer Cells
Current Drug Targets Dissecting the Therapeutic Potency of Antimicrobial Peptides Against Microbial Biofilms
Current Protein & Peptide Science Molecular Signatures of Biomarkers in Cancer Development, Diagn osis, and its Prognostic Accuracy
Current Biomarkers (Discontinued) In silico Methods for Designing Antagonists to Anti-apoptotic Members of Bcl-2 Family Proteins
Mini-Reviews in Medicinal Chemistry Strategies for Biology- and Molecular-Based Treatment of Myelodysplastic Syndromes
Current Drug Targets Genetic Modification of Natural Killer Cells for Leukemia Therapies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Intramammary Application of Non-Methylated-CpG Oligodeoxynucleotides (CpG) Inhibits both Local and Systemic Mammary Carcinogenesis in Female BALB/c Her-2/neu Transgenic Mice
Current Cancer Drug Targets Targeting Cytotoxic Conjugates of Somatostatin, Luteinizing Hormone- Releasing Hormone and Bombesin to Cancers Expressing Their Receptors: A “Smarter” Chemotherapy
Current Pharmaceutical Design A Progressive Review of V600E-B-RAF-Dependent Melanoma and Drugs Inhibiting It
Mini-Reviews in Medicinal Chemistry New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics
Current Topics in Medicinal Chemistry Removal of the Tag from His-tagged ILYd4, a Human CD59 Inhibitor, Significantly Improves its Physical Properties and its Activity
Current Pharmaceutical Design Bortezomib as an Antitumor Agent
Current Pharmaceutical Biotechnology Current Strategies to Target the Anti-Apoptotic Bcl-2 Protein in Cancer Cells
Current Medicinal Chemistry Ribonucleotide Reductase: A Critical Enzyme for Cancer Chemotherapy and Antiviral Agents
Recent Patents on Anti-Cancer Drug Discovery A Case of Neurosarcoidosis Mimicking Brain Tumor
Current Medical Imaging Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes
Current Genomics Actinium-225 in Targeted Alpha-Particle Therapeutic Applications
Current Radiopharmaceuticals Signal Transduction Pathway Regulated by Genistein and its Therapeutic Use
Current Signal Transduction Therapy Ring Opening of Tetrazole via Unusual Vilsmeir-Haack Reaction Forming Novel Triazenes
Letters in Organic Chemistry Application of Charge Transfer Reactions for the Quantitative Spectrophotometric Determination of Cyclophosphamide in Pure and Pharmaceutical Formulation
Current Pharmaceutical Analysis